Keith A. Katkin has served as our Principal Executive Officer since May 2018, a member of our board of directors since July 2018, and as the President and Chief Executive Officer of Urovant Sciences Inc. (USI) since September 2017. From March 2007 through January 2016, he was President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he led the company through its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. He also served as a member of the board of directors of Avanir from 2007 to 2016. Mr. Katkin joined Avanir in July 2005 as the Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team. From 2004 to 2005, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a biopharmaceutical company, until it was acquired by Ortho-McNeil Pharmaceutical, Inc., a subsidiary of Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Inc., Amgen Inc. and Abbott Laboratories. Mr. Katkin currently serves as the chairman of the board of directors of Novus Therapeutics, Inc., and as a director of Syndax Pharmaceuticals Inc. and Rigel Pharmaceuticals, Inc., all of which are publicly traded biopharmaceutical companies. Mr. Katkin earned a B.S. in Business and Accounting from Indiana University and an M.B.A. from the Anderson School at University of California, Los Angeles.
Cornelia Haag-Molkenteller, M.D., Ph.D. has served as the Chief Medical Officer of USI since April 2018. From April 2015 to March 2018, Dr. Haag-Molkenteller was the Vice President in Clinical Development at Allergan plc (previously Allergan Inc.), and from November 2007 to March 2015, the Vice President in Global Drug Development. While at Allergan, she led clinical development of onabotulinumtoxinA (BOTOX) for OAB and neurogenic detrusor overactivity. From 1988 to 2006, she was the Vice President of Clinical Program Leadership at Schwarz Biosciences GmbH. Dr. Haag-Molkenteller earned an M.D. and Ph.D. from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Michael McFadden has served as the Chief Commercial Officer of USI since January 2018. From April 2015 to January 2017, Mr. McFadden was the Senior Vice President for Commercial at Avanir Pharmaceuticals, Inc., where he led Avanir’s sales and marketing efforts, and from May 2010 to March 2015, the Vice President of U.S. Sales and Managed Markets. From July 2007 to April 2010, Mr. McFadden was the Senior Director, Managed Markets at Amylin Pharmaceuticals Inc., and from and from 2004 to 2007, a Regional Sales Director. While at Amylin, he launched two first-in-class diabetes products. From 2001 to 2003, Mr. McFadden was a State Purchasing Director at Pharmacia Corporation (prior to its acquisition by Pfizer Inc.). Mr. McFadden has nearly 30 years of pharmaceutical commercialization experience. Since July 2017, Mr. McFadden has also been an advisor to Akhu Therapeutics, Inc. Mr. McFadden earned a B.A. in Business Administration from the University of Louisiana at Monroe.
Christine G. Ocampo has served as our Principal Financial and Accounting Officer since May 2018, and as the Senior Vice President and Chief Accounting Officer of USI since October 2017. From September 2015 to May 2017, Ms. Ocampo was the Senior Vice President and Chief Financial Officer of Otic Pharma, Ltd., until it was acquired by Novus Therapeutics, after which she served as the Chief Financial and Compliance Officer until July 2017, and as a consultant from July 2017 to October 2017. Ms. Ocampo has over 20 years of accounting and finance experience, including over 11 years as the head of Finance for publicly traded companies in the healthcare industry. From 2007 to September 2015, Ms. Ocampo served in various roles at Avanir, including Vice President of Finance, Chief Accounting Officer and Vice President of Finance, Chief Compliance Officer and Secretary. From 2001 to 2006, Ms. Ocampo served as the Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer, Secretary and Vice President, Corporate Controller of Cardiogenesis Corporation (now CryoLife, Inc.), a publicly traded medical device company. From 1996 to 1997, Ms. Ocampo held a management role in Finance at Mills-Peninsula Health Systems in Burlingame, California, and from 1994 to 1996, served as an auditor for Ernst & Young LLP. Ms. Ocampo earned a B.A. in Accounting from Seattle University and is a licensed Certified Public Accountant in the state of Washington.
Bryan E. Smith has served as the General Counsel of Urovant Sciences since April 2018. Mr. Smith most recently served as Associate Vice President and Senior Counsel at Allergan, where he was chief counsel to the company’s Urology, Neurology, Aesthetics, and Dermatology business units. Mr. Smith also led Allergan’s anti-counterfeiting and anti-diversion efforts in close cooperation with the U.S. Food & Drug Administration’s Office of Criminal Investigations and other federal, state, and international law enforcement agencies. Prior to joining Allergan, Mr. Smith was a litigator at Gibson, Dunn & Crutcher LLP. Mr. Smith received his B.A. in Political Science from Brigham Young University and his J.D. from the University of Southern California Law School. After graduating from law school, Mr. Smith was a law clerk to the Honorable Cormac J. Carney in the United States District Court for the Central District of California.
Nori Ebersole has served as the Senior Vice President and Chief Human Resources Officer of USI since December 2017. From September 2015 to December 2017, Ms. Ebersole was the Chief Human Resources Officer and Chief Talent Officer at Paul Hastings LLP. From April 1997 to June 2015, Ms. Ebersole served in various roles at Allergan, including most recently as Vice President, Human Resources from January 2014 to June 2015, partnering with executives globally on key strategic initiatives in the Urology, Neurology, Dermatology, Ophthalmology and Aesthetics business units. At Allergan, Ms. Ebersole led numerous commercial and R&D expansions, compensation planning, leadership development and retention strategies. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business.
David N. Hovland, Ph.D., has served as the Senior Vice President Global Regulatory Affairs since March 2018. Dr. Hovland has over 18 years of experience in R&D in the pharmaceutical industry and has contributed to the global development and registration of multiple small molecule and biotechnology-derived pharmaceutical products. From 2015 to 2018, he served as Vice President, Global Regulatory Affairs at Allergan where he was the Global Regulatory Affairs Therapeutic Area Head for Neurology, Urology and Dermatology. Prior to that he served as Head of the Global Regulatory Operations function at Allergan, as a Senior Director from 2010 to 2013 and as a Vice President from 2013 to 2015. From 2006 to 2010, Dr. Hovland was a Director in the Global Regulatory Affairs and Safety department at Amgen, where he served as a global regulatory strategy leader on pharmaceutical development teams. Dr. Hovland started his career in the pharmaceutical industry in nonclinical development as a study director and project team toxicologist, first at Allergan from 1999 to 2002 and subsequently at Amgen from 2002 to 2006. Dr. Hovland earned his Ph.D. in Environmental Health Sciences from the School of Public Health at the University of California, Los Angeles, and his B.S. in Bioresource Sciences from the College of Natural Resources at the University of California, Berkeley.